Increased lipoxin B4 levels in children with atopic dermatitis

Main Article Content

Himmet Haluk Akar
Mikdat Yildiz

Abstract

Background Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the pediatric population. The pathophysiology of AD is complex and not clearly understood. The role of lipoxin B4 (LXB4), an anti-inflammatory mediator, has not been sufficiently investigated in children with AD to our knowledge.


Objective To compare the levels of serum LXB4 between children with AD and healthy controls.  


Methods Three groups of children were enrolled in this study: a SPT-Pos group (skin prick test positive 21 subjects with AD), a SPT-Neg group (skin prick test negative 22 subjects with AD), and a control group (23 healthy subjects). Subjects’ serum LXB4 levels of were measured with an ELISA technique. Also, eosinophil counts and total immunoglobulin E (IgE) levels were compared among all groups.


Results We observed significantly higher LXB4 levels in AD patients than in controls. Also, LXB4 levels were significantly higher in the SPT-Pos group than in the SPT-Neg group and control group. However, no significant difference was observed between the SPT-Neg and control groups.


Conclusion The LXB4 may have an anti-inflammatory mediator role in the pathogenesis of AD in children. The LXB4-associated pathways may be considered in the development of novel therapeutic approaches for the treatment of patients with AD.

Article Details

How to Cite
1.
Akar H, Yildiz M. Increased lipoxin B4 levels in children with atopic dermatitis. PI [Internet]. 11Oct.2019 [cited 14Nov.2019];59(5). Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2227
Section
Pediatric Allergy Immunology
Received 2019-07-11
Accepted 2019-10-11
Published 2019-10-11

References

1. Sehra S, Serezani APM, Ocana JA, Travers JB, Kaplan MH. Mast cells regulate epidermal barrier function and the development of allergic skin inflammation. J Invest Dermatol. 2016;136:1429-37.
2. Campana R, Dzoro S, Mittermann I, Fedenko E, Elisyutina O, Khaitov M, et al. Molecular aspects of allergens in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2017;17:269-77.
3. de Graauw E, Beltraminelli H, Simon HU, Simon D. Eosinophilia in Dermatologic Disorders. Immunol Allergy Clin North Am. 2015;35:545-60.
4. Karra L, Haworth O, Priluck R, Levy BD, Levi-Schaffer F. Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice. Mucosal Immunol. 2015;8:852-62.
5. Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Crit Rev Oral Biol Med. 2003;14:4-12.
6. Levy BD, Bertram S, Tai HH, Israel E, Fischer A, Drazen JM, et al. Agonist-induced lipoxin A4 generation: detection by a novel lipoxin A4-ELISA. Lipids. 1993;28:1047-53.
7. Planagumà A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med. 2008;178:574-82.
8. Hanifin, J.M. and Rajka, G.: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44–47.
9. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med. 2002;165:1531-5.
10. Martin N, Ruddick A, Arthur GK, Wan H, Woodman L, Brightling CE, et al. Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation. PLoS One. 2012;7:e43545.
11. Gewirtz AT, Fokin VV, Petasis NA, Serhan CN, Madara JL. LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. Am J Physiol. 1999;276:C988-94.
12. Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AE, Spur BW. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-Lmethionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond). 1989;77:195-203.
13. Eke GH, Tahan F, Gokahmetoglu S, Saraymen B. Decreased levels of lipoxin A4 and annexin A1 in wheezy infants. Int Arch Allergy Immunol. 2014;163:193-7.
14. Tahan F, Eke GH, Bicici E, Saraymen B, Akar HH. Increased postexercise lipoxin A4 levels in exhaled breath condensate in asthmatic children with exercise-induced bronchoconstriction. J Investig Allergol Clin Immunol. 2016;26:19-24.
15. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br J Dermatol. 2013;168:172-8.